Aug 15 (Reuters) - Scorpion Capital disclosed a short position in Soleno Therapeutics SLNO.O on Friday, citing issues with the drug developer's recently approved treatment Vykat XR.
Shares of Soleno declined 15% in premarket trading. The company did not immediately respond to a Reuters request for comment.